Skip to main content

Table 1 Patients’ clinicopathological features

From: TGFβ1 pathway components in breast cancer tissue from aggressive subtypes correlate with better prognostic parameters in ER-positive and p53-negative cancers

Parameter

General BC

(n = 34)

LB-HER2+

(n = 9)

HER2

(n = 9)

TN

(n = 16)

Age

 Median (IQR)

56 (18)

57 (21)

51 (13)

57 (22)

 Mean (SD)

56 (12)

57 (11)

49 (10)

59 (14)

 < 40 [n (%)]

3 (8.8)

0 (0.0)

2 (22.2)

1 (6.3)

 40–49 [n (%)]

9 (26.5)

3 (33.3)

2 (22.2)

4 (25.0)

 50–59 [n (%)]

9 (26.5)

2 (22.2)

3 (33.3)

4 (25.0)

 60–69 [n (%)]

8 (23.5)

3 (33.3)

2 (22.2)

3 (18.8)

 70–79 [n (%)]

3 (8.8)

1 (11.1)

0 (0.0)

2 (12.5)

 > 80 [n (%)]

2 (5.9)

0 (0.0)

0 (0.0)

2 (12.5)

Histological subtype [n (%)]

 DCIS

31 (91.2)

7 (77.8)

8 (88.9)

16 (100)

 IDC

2 (5.9)

1 (11.1)

1 (11.1)

0 (0)

 Mixed (IDC and ILC)

1 (2.9)

1 (11.1)

0 (0)

0 (0)

 Other

    

Tumor size [n (%)]

 Median (IQR)

3.0 (2.3)

2.4 (0.7)

2.5 (1.6)

4.0 (1.6)

 Mean (SD)

3.4 (1.6)

2.4 (0.9)

3.0 (1.1)

4.2 (1.8)

 < 1.5 cm

2 (5.9)

2 (22.2)

0 (0.0)

0 (0.0)

 1.51–3.0 cm

13 (38.2)

5 (55.6)

5 (55.6)

3 (18.8)

 > 3.0 cm

19 (55.9)

2 (22.2)

4 (44.4)

13 (81.2)

Histopathological Grade [n (%)]

 I

1 (2.9)

1 (11.1)

0 (0.0)

0 (0.0)

 II

10 (29.4)

5 (55.6)

3 (33.3)

2 (12.5)

 III

23 (67.6)

3 (33.3)

6 (66.7)

14 (87.5)

Ki67 [n (%)]

 Low

1 (3.0)

1 (11.1)

0 (0.0)

0 (0.0)

 Intermediate

15 (45.5)

7 (77.8)

4 (44.4)

4 (26.7)

 High

17 (51.5)

1 (11.1)

5 (55.6)

11 (73.3)

 Unknown

1

0

0

1

p53 [n (%)]

 Negative

13 (40.6)

5 (62.5)

2 (22.2)

6 (40.0)

 Positive

19 (59.4)

3 (37.5)

7 (77.8)

9 (60.0)

 Unknown

2

1

0

1

Lymph node metastasis [n (%)]

 Negative

15 (44.1)

3 (33.3)

5 (55.6)

7 (43.8)

 Positive

19 (55.9)

6 (66.7)

4 (44.4)

9 (56.3)

Disease Stage [n (%)]

 0 (DCIS)

2 (5.9)

1 (11.1)

1 (11.1)

0 (0.0)

 I

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 II

19 (55.9)

5 (55.6)

5 (55.6)

9 (56.3)

 III

11 (32.4)

3 (33.3)

2 (22.2)

6 (37.5)

 IV

2 (5.9)

0 (0.0)

1 (11.1)

1 (6.3)

  1. DCIS Ductal carcinoma in situ, IDC Invasive ductal carcinoma, ILC Invasive lobular carcinoma, IQR interquartile range, SD Standard deviation